Headaches occur in the general population at remarkably high baseline rates
for example, coronary heart disease, or in those that have a BMI lower than 35kg/m 2 and for whom insulin therapy would have significant occupational implications[15]
"You can't just make up what dose to take," he says
4 webinar, New Weight Loss Drugs Raise Issues of Coverage, Cost, Access and Equity, for which the recording is posted here.
Almost 50% of people taking GLP-1 medication think it's okay to ask someone about their use of weight-loss medication, but only in certain situations, such as: Close personal relationships: 64% Concern for health: 62% Professional/healthcare settings: 60% If they have posted about their weight loss journey online: 40% 3 in 4 people taking GLP-1 medication are transparent about their weight-loss medication use
Our healthcare professionals monitor patients progress and any adverse effects to determine which medication better suits their needs
